These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 35891326)
1. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. Grikscheit K; Rabenau HF; Ghodratian Z; Widera M; Wilhelm A; Toptan Grabmair T; Hoehl S; Layer E; Helfritz F; Ciesek S Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891326 [TBL] [Abstract][Full Text] [Related]
2. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals. Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay. Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S Front Immunol; 2022; 13():1039163. PubMed ID: 36505453 [TBL] [Abstract][Full Text] [Related]
4. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals. Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601 [TBL] [Abstract][Full Text] [Related]
5. Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals. Faas MR; Mak WA; Markus HY; van der Zwan EM; van der Vliet M; Koeleman JGM; Ong DSY Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560542 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study. Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I; Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728 [TBL] [Abstract][Full Text] [Related]
7. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867 [TBL] [Abstract][Full Text] [Related]
8. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study. Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634 [TBL] [Abstract][Full Text] [Related]
9. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053 [TBL] [Abstract][Full Text] [Related]
10. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152 [TBL] [Abstract][Full Text] [Related]
12. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5. Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738 [TBL] [Abstract][Full Text] [Related]
13. Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination. Suntronwong N; Assawakosri S; Kanokudom S; Yorsaeng R; Auphimai C; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892491 [TBL] [Abstract][Full Text] [Related]
14. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864 [TBL] [Abstract][Full Text] [Related]
15. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies. Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299 [TBL] [Abstract][Full Text] [Related]
16. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination. Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552 [TBL] [Abstract][Full Text] [Related]
17. Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern. Diem G; Dichtl S; Zaderer V; Lass-Flörl C; Reindl M; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Wilflingseder D; Posch W Microbiol Spectr; 2023 Aug; 11(5):e0179323. PubMed ID: 37551989 [TBL] [Abstract][Full Text] [Related]
18. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1. Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS bioRxiv; 2022 Nov; ():. PubMed ID: 36380757 [TBL] [Abstract][Full Text] [Related]
19. Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants. Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL bioRxiv; 2022 Jul; ():. PubMed ID: 35898337 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. Roth N; Gergen J; Kovacikova K; Mueller SO; Ulrich L; Schön J; Halwe NJ; Fricke C; Corleis B; Dorhoi A; Hoffmann D; Beer M; Maione D; Petsch B; Rauch S Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]